All marketing authorization holders of medicine are hereby informed that NMRA decided to revoke the decision taken to register only Extended Release Donepazil Hydrochloride Tablets based on the recommendation given by 77th Medicines Evaluation Committee held on 25th April 2023.

‍

(Date : 24 May 2023)

‍